duration (ED) (C:749+-18.6, 0:529+-22.2 sec) and physical working capacity (PWC-170/kg LBM) (C :3.5t-0.2, 0:2.2+-O.2W/kg LBM) were decreased in the 0 (pd.OOl).The relationship of anthropometric and atherosolerotic risk parameters (IRI and lipoprotein-ch classes) with the above fitness factors was investigated using multiple regression analysis. The relationship of blood pressure, ECG and atherosclerotic risk factors was also studied.The variation of ED was mainly influenced by rel.bw.(R=0.77) and by IRI and LDL-ch (R=0.7).LBM (R=0.53) and IRI and LDL/HDL-ch (R=0.59) accounted for the variation of WC-170/kg LBM.It is suggested that beside body composition IRI level and LDL/HDL-ch ratio are important factors related to physical fitness. To providc rcfcrence data for normal children, serum immunoreactlve erythropoietin (siEp) was estimated by radioimmunoassay in samplcs from 130 healthy children, 57 girls and 73 boys, with ages b-tween 1 month and 16 years. Thc children were referred either for mlnor complaints or for elective surgery. In 128 of the childrcn the (geometric) mean estimate of siEp was 15.8 mIU/ml with 75% range (the range within which 95% of the observations are prcdicted to fall) 9.1-27.6 mIU/ml. The remaining two children, both girls agcd 9.5 and 9.8 years, had estimates of slEp >256mIU/ml. In both tlb and PCV wcre normal and we have no explanation for these atypical findings. Children in the youngest age group, 0.9 to 2.0 monLhs (n~4), had the lowcst estimates of siEp, mean 8.0 with rnngc 4-13 mIU/n~l. This was lor~cr than the estimates in children aged 2.0 to 3.5 months (n=6), in whom mean siEp was 17.6 ~rith range 12-38 mIU/ml (Wilcoxon rank sum test, p=0.019). Otherwise there was no relation bctncen siEp and thc variables lib, PCV, age and sex.
Estimates of siEp in the 120 chlldrcn were not significantly diffcrent rrom thouc in 22 normal adults invcstigated simultaneously (mean 16.2 mIU/nl, 95% range 11.2-23.3 mIU/ml).
RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF

ANAEMIA IN CHILDREN WITH E N D -~T A~E RENAL FAILURE
--MAINTAINED BY HAEMODIALYSIS Susan P A Rigden, Giovanni Montini, Max C Morris, Kenneth C A Clark,Laura L Tomllnson, Mary P Cotes. Evelina Children's Hospital, Guy's Hospital, London SE1. 6 children maintained on chronic haemodialysis (4M, 2F age range 3y 1111-14y 10m1)1 have been entered into a study to establish the efficacy and safety of recombinant human erythropoietin irHuEPO) in the treatment of anaemia due to end-stage renal disease (ESRD).
rliuEPO has been given in an escalating dose regimen, 3x weekly by IV injection at the end of each dialysis. Efficacy has been assessed by 3x weekly blood counts including reticulocytes (retics), monthly determinations of HLA antibodies and assessments of cardiovascular status and quality of life before commencing rHuEPO and 4 weeks after reaching target haemoglobin (Hb). Biochemical profiles have been checked weekly and iron status assessed monthly.
The first 2 patients studied have responded with increased retic counts and Hb levels. (Pt 1 , baseli im we have run a controlled randmized study in young(100g) rats 1ool:ing for following parameters: food intake(FI), weight gain(rE), grarth(G1, organ (heart, liver, spleen, kidney -corrected for body weight), blood pressure(BP) , thrmhcytes(T), and p t a ssium(1:). 20 aninmls w r e subtotally neptrectcmized and receive3 either 4 IU rllEPO sc/d or solvent for 4 weeks with free access to food(urea 21.5 ml/l). 20 sham-operated pair fed and 20 ad lib fed anbls with and without rhEPO respectively, served as controls(urea 5.9 ml/l). Although RA could be prevented by r h E W (Hct 51 vs 44%, p<0.05), it did neither affect FI nor !G,G,T and K. Mauever, DP was slightly increased in the rhEPO treated uremic animals(135'10 vs 121-7 rm Ag, p<0.05) as was the spleen weight whereas the other organ masses r a i n e d wiaffected by rwhich could not prevent myocardial hyprtrophy.Data suggest that treatrent with rh!ZO will not mliorate uremia induced stunting and myocardial hypfrtrophy and usually leads to hy~crtension which rus'i be regard4 as the most serious side effect. 
IMMUNOREACTIVE ERYTHROPOIETlN AND ERYTHROPOIESIS
